Currently, Evommune Inc [EVMN] is trading at $17.59, down -1.79%. An important factor to consider is whether the stock is rising or falling in short-term value. The EVMN shares have gain 10.49% over the last week, with a monthly amount drifted -9.24%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley started tracking the stock with Overweight rating on December 01, 2025, and set its price target to $36. On December 01, 2025, Leerink Partners initiated with an Outperform rating and assigned a price target of $42 on the stock. Evercore ISI started tracking the stock assigning an Outperform rating and suggested a price target of $40 on December 01, 2025. Cantor Fitzgerald initiated its recommendation with an Overweight.
This stock has fluctuated between a low of $13.89 and a high of $24.03 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $39.33 within the next 12 months. Evommune Inc [NYSE: EVMN] shares were valued at $17.59 at the most recent close of the market. An investor can expect a potential return of 123.59% based on the average EVMN price forecast.
Analyzing the EVMN fundamentals
Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -5.41%, Pretax Profit Margin comes in at -4.53%, and Net Profit Margin reading is -4.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is 0.51 and Total Capital is -0.95. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.21 points at the first support level, and at 16.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.18, and for the 2nd resistance point, it is at 18.78.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Evommune Inc [NYSE:EVMN] is 7.76. On the other hand, the Quick Ratio is 7.76, and the Cash Ratio is 2.57.
Transactions by insiders
Recent insider trading involved Hopfner Robert Lorne, Director, that happened on Dec 19 ’25 when 1000.0 shares were purchased.
